Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 11/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | SNCA | P37840 | 1/20 | 0.41 |
| ▸ | LSS | P48449 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10870487 | 0.91 | CYP3A4 (0.50) | CYP3A4NPC1POLBMAPTRAB9A | |
| SCHEMBL9717280 | 0.88 | ALDH1A1 (0.51) | CYP3A4NPC1POLBMAPTRAB9A | |
| SCHEMBL10349842 | 0.87 | CYP3A4 (0.41) | ELANECYP3A4NPC1POLBMAPT | |
| SCHEMBL6152948 | 0.86 | CYP3A4 (0.46) | ELANECYP3A4NPC1POLBMAPT | |
| SCHEMBL9717273 | 0.84 | ALDH1A1 (0.48) | ELANECYP3A4NPC1POLBMAPT | |
| SCHEMBL9717293 | 0.84 | HSD17B10 (0.53) | ALDH1A1HSD17B10LMNA | |
| SCHEMBL12014962 | 0.83 | SNCA (0.43) | ELANECYP3A4NPC1POLBMAPT | |
| SCHEMBL7270769 | 0.83 | THRB (0.44) | CYP3A4NPC1POLBMAPTRAB9A | |
| SCHEMBL9174753 | 0.83 | CYP3A4 (0.43) | CYP3A4NPC1POLBMAPTRAB9A | |
| SCHEMBL6151946 | 0.83 | ELANE (0.46) | ELANECYP3A4NPC1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1511750-A1 | PROCESS FOR THE PREPARATION OF FAMCICLOVIR | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-03-09 | — | — | EP | claimed |
| US-20040266795-A1 | Process for the preparation of famciclovir | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-12-30 | — | — | US | claimed |
| WO-2004099208-A1 | PROCESS FOR THE PREPARATION OF FAMCICLOVIR | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-11-18 | — | — | WO | claimed |
| EP-1556383-A1 | PROCESS FOR PREPARING FAMCICLOVIR | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-07-27 | — | — | EP | disclosed |
| US-20050143400-A1 | Process for preparing famciclovir | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-06-30 | — | — | US | disclosed |
| WO-2005026167-A1 | PROCESS FOR PREPARING FAMCICLOVIR | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-03-24 | — | — | WO | disclosed |
| EP-1511750-A1 | PROCESS FOR THE PREPARATION OF FAMCICLOVIR | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2005-03-09 | — | — | EP | disclosed |
| US-20040266795-A1 | Process for the preparation of famciclovir | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-12-30 | — | — | US | disclosed |
| WO-2004099208-A1 | PROCESS FOR THE PREPARATION OF FAMCICLOVIR | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266795-A1 | Process for the preparation of famciclovir | ADH1C, CPS1, PAICS | ELANE 4317/4885CYP3A4 22/4885NPC1 2217/4885 |
| US-20050143400-A1 | Process for preparing famciclovir | MTAP, TPMT, RFC1 | ELANE 4502/4885CYP3A4 377/4885NPC1 1923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.